Association of 5α-reductase inhibitor prescription with immunotherapy efficacy in metastatic renal cell carcinoma: a multicenter retrospective analysis.

J Immunother Cancer · 2025 · PMC11865730 · PMID 40010773

Europe PMC DOI

hedged sentence

0.1003

closest p · 2.0× alpha

0.1003

boldest claim

The sentences

showed a trendp=0.1003not close (p > 0.1)

The 1-year OS rates showed a trend toward improvement in the 5-ARI group (72.7% vs 61.1%, p=0.1003), but statistical significance was not reached.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.